Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats

@article{Auclair2007PutativeAW,
  title={Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats},
  author={Agn{\`e}s L. Auclair and Alexandra Galinier and Jo{\"e}l Besnard and Adrian Newman-Tancredi and Ronan Depoort{\`e}re},
  journal={Psychopharmacology},
  year={2007},
  volume={193},
  pages={45-54}
}
IntroductionPrepulse inhibition (PPI) of the startle reflex has been extensively studied because it is disrupted in several psychiatric diseases, most notably schizophrenia. In rats, and to a lesser extent, in humans, PPI can be diminished by dopamine (DA) D2/D3 and serotonin 5-HT1A receptor agonists. A novel class of potential antipsychotics (SSR181507, bifeprunox, and SLV313) possess partial agonist/antagonist properties at D2 receptors and various levels of 5-HT1A activation.Materials and… Expand
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties
TLDR
Interestingly, pretreatment of HEK293-h5-HT7a cells with forskolin enhanced basal AC activity and revealed inverse agonist properties for both typical and atypical antipsychotics as well as for aripiprazole. Expand
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
TLDR
Compounds possessing “balanced” 5- HT1A receptor agonism and D2 antagonism and, in some cases, combined with other beneficial properties, such as 5-HT2A receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction. Expand
Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: A possible role of hyperforin
TLDR
It is concluded that serotoninergic 5-HT1A and 5- HT2A, alpha-adrenergic and dopaminergic D1 receptors are involved in the disruptive effect of St. John's wort extract on PPI response in rats, and hyperforin, and not hypericin, is one of the active ingredients responsible for St.John's worts wort-induced PPI disruption with no relation to apoptotic processes. Expand
F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists
TLDR
F15599, in models of memory/cognition, has a more favourable profile than F13714 and 8-OH-DPAT, which suggests that preferential activation of post-synaptic 5-HT(1A) receptors could prove useful in pathologies characterized by cognitive/memory deficiencies, such as schizophrenia and depression. Expand
Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats
TLDR
D2 partial agonists may constitute a new group of antipsychotics that alters brain activity in regions relevant to schizophrenia, and has a pharmacological profile that differs for the two psychosis models tested and does not match the typical or atypical psychotics. Expand
Aripiprazole in an Animal Model of Chronic Alcohol Consumption and Dopamine D2 Receptor Occupancy in Rats
TLDR
Chronic alcohol intake results in a significant increase in exposure of aripiprazole in plasma and brain and striatal D2R occupancy in CASA rats, thus aripIPrazole dose might have to be decreased. Expand
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders.
TLDR
The data suggest that 5-HT1A receptor biased agonists constitute potentially superior pharmacological agents for treatment of CNS disorders involving serotonergic mechanisms. Expand
Serotonergic approaches in the development of novel antipsychotics
TLDR
The main scope of this review will evaluate the major preclinical and clinical pharmacological findings concerning the strategies and pharmacological agents developed to treat the sequalae of schizophrenia, and compare their therapeutic potential with currently available antipsychotics; however, recent developments at other emerging serotonergic targets will also be considered. Expand
Aripiprazole, A Drug that Displays Partial Agonism and Functional 
Selectivity
TLDR
A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms. Expand
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
TLDR
The hypothesized effects of aripiprazole on cell-protective mechanisms and neurite growth, as well as the differential effects on intracellular pathways, suggest further exploration of these targets by novel and future biased ligand compounds. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 63 REFERENCES
Actions of Novel Antipsychotic Agents on Apomorphine-Induced PPI Disruption: Influence of Combined Serotonin 5-HT1A Receptor Activation and Dopamine D2 Receptor Blockade
TLDR
Antipsychotics possessing agonist efficacy at 5-HT1A receptors exhibit diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D2 and 5- HT1A activities, suggesting that they may display distinct activity on some aspects of gating deficits in schizophrenic patients. Expand
Novel antipsychotic agents with 5-HT1A agonist properties: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats
TLDR
Data show that 5-HT(1A) receptor activation reduces the cataleptogenic potential of novel antipsychotic agents but indicate marked diversity in the contribution of 5- HT( 1A) and/or other mechanisms to the profiles of the drugs. Expand
5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release
TLDR
The results suggest that the atypical APDs via 5‐HT2A and D2 receptor blockade, regardless of intrinsic 5-HT1A affinity, may promote the ability of 5- HT1A receptor stimulation to increase mPFC DA release, and provide additional evidence that coadministration of 5‐ HT2A antagonists and typical APDs, which are D2 antagonists, may facilitate 5‐ht1A agonist activity. Expand
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
TLDR
The data indicate that aripiprazole has low efficacy and modest affinity at 5-HT1A receptors, whereas bifeprunox has low affinity but high efficacy, and SSR181507 has intermediate efficacy but high affinity, and is likely to have more prominent 5- HT1A receptor agonist properties. Expand
SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats
TLDR
The data suggest that, in addition to its atypical antipsychotic profile and antidepressant/anxiolytic activities, SSR181507 has a potential therapeutic activity in another key feature of schizophrenia poorly controlled by current antipsychotics, namely deterioration in social functioning. Expand
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity
TLDR
The pharmacological profile of SSR181507 suggests that it should control the symptoms of schizophrenia, in the absence of extrapyramidal signs and cognitive deficits, with the additional benefit of antidepressant/anxiolytic activities. Expand
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
TLDR
Ant antipsychotics display varying efficacies at serotonin 5-HT1A and dopamine D2S receptors which may play a major role in their differential functional profiles in blocking the diverse symptoms of schizophrenia. Expand
5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
Background: Ziprasidone (Zeldox) is a novel antipsychotic with a unique combination of antagonist activities at monoaminergic receptors and transporters and potent agonist activity at serotoninExpand
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit
TLDR
Results suggest that SSR181507 can alleviate disturbances of novelty discrimination in a social context in rats, and that this paradigm may represent a suitable animal model of selective attention deficits observed in schizophrenia. Expand
Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects
TLDR
The present data suggest that 5-HT1A agonists with intermediate or high, but not low, intrinsic activity may abolish the extrapyramidal effects of neuroleptics. Expand
...
1
2
3
4
5
...